FY2025 Earnings Forecast for EPRX Issued By HC Wainwright

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Research analysts at HC Wainwright boosted their FY2025 earnings estimates for Eupraxia Pharmaceuticals in a note issued to investors on Wednesday, November 12th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.67) per share for the year, up from their prior estimate of ($0.68). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q4 2025 earnings at ($0.11) EPS.

EPRX has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, October 8th. Cantor Fitzgerald began coverage on Eupraxia Pharmaceuticals in a research report on Thursday, July 24th. They set an “overweight” rating and a $11.00 target price on the stock. Finally, Leede Financial raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.67.

Eupraxia Pharmaceuticals Stock Down 3.9%

NASDAQ:EPRX opened at $6.34 on Friday. The stock has a market capitalization of $227.99 million, a price-to-earnings ratio of -7.29 and a beta of 1.47. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $7.19. The firm has a 50 day moving average of $5.77 and a 200 day moving average of $5.09.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Quadrature Capital Ltd purchased a new stake in Eupraxia Pharmaceuticals in the second quarter valued at approximately $61,000. TCI Wealth Advisors Inc. acquired a new stake in Eupraxia Pharmaceuticals during the 3rd quarter valued at approximately $65,000. Bank of America Corp DE boosted its holdings in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after acquiring an additional 10,059 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after acquiring an additional 16,017 shares during the period. Finally, Guardian Partners Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals in the third quarter worth $147,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.